Skip to main content

Advertisement

Table 3 Studies of immune checkpoint inhibitors in ovarian cancer with reported results

From: The role of immune checkpoint inhibition in the treatment of ovarian cancer

Immunotherapy agent(s) Trial number Disease status Phase N Results (N; duration) G3/4 adverse events Reference
Ipilimumab   recurrent EOC, previously treated with GVAX vaccine I 9 PR (1; 35+ mos.) SD (3; 1 for 6+ mos.) diarrhea Hodi et al. [50]
BMS-936559 (anti-PD-L1) NCT00729664 recurrent EOC I 17 6% PR (1; 1.3+ mos.) 18% SD (3; 6+ mos.) infusion-related reaction, adrenal insufficiency Brahmer et al. [80]
Nivolumab   platinum resistant EOC II 20 10% CR (2; 11+ mos.) 5% PR (1; 11+ mos.) 30% SD (6; 1 for 11+ mos.) lymphocytopenia, hypoalbuminemia, elevated ALT, rash, fever, anemia Hamanishi et al. [25]
Pembrolizumab NCT02054806 recurrent EOC, PD-L1 positive Ib 26 4% CR (1; 6+ mos.) 8% PR (2; 6+ mos.) 23% SD (8; 2 for 6+ mos.) transaminitis Varga et al. [26]
Ipilimumab NCT01611558 recurrent EOC II 40 10% BRR (4; NA) NA clinicaltrials.gov [27]
Avelumab NCT01772004 recurrent EOC Ib 124 10% PR (12; 4 for 6+ mos.) 44% SD (55; NA) rash, edema, elevated amylase/lipase, arthritis, colitis, hyperglycemia/DM Disis et al. [28]
Durvalumab + Olaparib NCT02484404a recurrent EOC I/II 10 PR (1; 11+ mos.) SD (7; 4+ mos.) Lymphopenia, anemia Lee et al. [29]
Durvalumab + Cediranib 4 PR (1; 7 mos.) SD (2; 1 for 6 mos.) Lymphopenia, anemia, nausea, diarrhea, hypertension, PE, pulmonary hypertension, fatigue, headache
  1. Abbreviations: N number of ovarian cancer patients treated, EOC epithelial ovarian cancer, CR complete response, PR partial response, SD stable disease, ALT alanine aminotransferase, BRR best response rate (CR/PR status not provided), mos. months, NA not available, DM diabetes mellitus; PE, pulmonary embolism
  2. aAs of data cut-off date: May 10, 2016